(thirdQuint)Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type.

 This trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, comparison trial to assess the efficacy and safety of aripiprazole in patients with agitation associated with Alzheimer's type dementia.

 Screening period is 4 weeks.

 Patients are randomly assigned to one of 4 groups, and treatment period is 10 weeks.

 Period of post-treatment observation is 30 days.

.

 Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type@highlight

To evaluate the efficacy (based on mean change in Cohen-Mansfield Agitation Inventory [CMAI] total score from baseline as the primary efficacy variable), dose-response, and safety of aripiprazole at 2, 3, and 6 mg/day in comparison with placebo in patients with agitation associated with Alzheimer's type dementia